iCAD stock traded up $0.03 during trading hours on Thursday, reaching $7.00. 3,295 shares of the company’s stock traded hands, compared to its average volume of 63,672. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.85 and a current ratio of 2.00. iCAD has a fifty-two week low of $2.42 and a fifty-two week high of $7.45. The firm has a market capitalization of $125.97 million, a price-to-earnings ratio of -18.13 and a beta of 1.15. The firm’s 50 day moving average is $6.31 and its 200-day moving average is $5.76.
iCAD (NASDAQ:ICAD) last released its earnings results on Thursday, August 1st. The technology company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. iCAD had a negative net margin of 43.88% and a negative return on equity of 61.62%. The company had revenue of $7.33 million for the quarter, compared to the consensus estimate of $6.69 million. Analysts predict that iCAD will post -0.58 EPS for the current year.
iCAD Company Profile
iCAD, Inc provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy.
Read More: How to calculate compound interest
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.